Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease (HR, 1.02).
|Articles|September 16, 2008
- October31 2004
- Volume 11
- Issue 20
Making Money
Advertisement
Compensation & Financial Survey
Physician's Money Digest
There are many surveys out and about that indicate what physicians earn each year. Here's another. According to the American Medical Group Association's 2004 (www.amga.org), following are the median annual compensations for the specialties of various readers:
Articles in this issue
about 18 years ago
A Life of Caring Ended Too Quicklyabout 18 years ago
Health Care Cost Controls—for Allabout 18 years ago
How to Mourn for Your Departed Moneyabout 18 years ago
Physician Recruitment: A Look at Job Trendsabout 18 years ago
Are You Facing a Medical Career Crisis?about 18 years ago
Consider a Path for Your Journey's Endabout 18 years ago
Ponder the State of Pension Plans Todayabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Why Insured Munis?about 18 years ago
Buy Equipment SoonAdvertisement
Related to this article
Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
4
Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study
5